A comprehensive view of Vertex Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
FDA approves Vertex Pharmaceutical's Casgevy and Bluebird Bio's Lyfgenia, the first cell-based gene therapies for sickle cell disease in patients 12 years and older; both treatments use patients' own blood stem cells, a major advantage in gene therapy
Published:
December 08, 2023
by U.S. Food and Drug Administration (FDA)
|
Ask us about our Government & Public Policy market view